Appendix VIII: Example of description page with table

[0351] In the evaluation phase, the results from the feasibility phase were used to select the appropriate doses required to attain a sustained delivery of GLP-1 for a 3-5 day effect. Eight mice were used in each group. Data on the baseline glucose levels were gathered for each mouse three days prior to drug dosing. A time 0 day blood sample (5 to 10 µL) was collected from the tail vein. The glucose level (mg/dL) was measured using a glucose analyser. Each animal was then dosed subcutaneously (SC) below the skin on the back. The amount of test article administered was based on the average body weight of the animal, and the total volume of the dose did not exceed 10 mL/kg. Blood samples of 5 to 10 µL (<0.5% of 2 mL blood volume for a 35 g mouse) were removed at the following time points: -3, -2, -1, 0, 0.04, 0.16, 0.33, 0.5, 1, 2, 3, 6 days.

[0352] Table 2 below describes the test compounds and the dose for each group of animals.

Space between text and table of at least 1 cm

TABLE 2

Test Compounds and Dose for Each Group of Animals

Treatment	Lot or Reference Nos.	Number of mice/group	Dose (µg)
Negative control (saline)	Baxter, Lot C645028	8	-
Positive control 2 (GLP-1)	American Peptide, lot T05128191	8	60, 120
G2PEG2Fmoc$_{20K}$-Lys$_{(26\ or\ 34)}$-GLP1	ZH 071805	8	420
G2PEG2Fmoc$_{40K}$-Lys$_{(26\ or\ 34)}$-GLP1	ZH 072305	8	420
G2PEG2Fmoc$_{20K}$-N^{ter}-GLP1	ZH 082405 ZH 092105	8	420
G2PEG2Fmoc$_{40K}$-N^{ter}-GLP1	ZH 082505 CP2F1 ZH 082505 CP2F2	8	420

Table border of at least 1.5 points